Advisory Group Issues Consensus Recommendations for Neuro-Behçet's Disease

Article

Agreed-upon guidelines include Neuro-Behçet's disease (NBD) diagnostic criteria and recommendations on when to consider NBD in a neurological patient.

Though it is a relatively uncommon condition, Neuro-Behçet’s disease (NBD) is a serious manifestation of Behcet’s disease that neurologists must consider in their differential diagnoses of inflammatory, infective, or demyelinating central nervous system disorders. However, evidence-based information on NBD diagnosis and management is scarce, and planning for such studies is challenging.

On behalf of the International Neuro-Behçet’s Advisory Group, Seema Kaira, MD, and colleagues developed expert consensus recommendations using an extensive literature review and wide consultations with an international advisory panel, followed by a Delphi exercise.

The agreed-upon guidelines — which were published online December 24, 2013, in the Journal of Neurology — include NBD diagnostic criteria with 2 levels of certainty and recommendations on when to consider NBD in a neurological patient, as well as on the use of various paraclinical tests. Management recommendations include the treatment of parenchymal NBD and cerebral venous thrombosis, the use of disease-modifying therapies, prognostic factors, and outcome measures.

Related Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.